About Biomea Fusion Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.biomeafusion.com/
Frequently Asked Questions
What is the 52-week range for BMEA?
The 52-week high is $2.99 and the 52-week low is $0.8719.
What is the P/E ratio for BMEA?
The P/E ratio data is currently unavailable.
What is the dividend yield for BMEA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -171.19%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.97.
Analyst Recommendation Trends
Wall Street analyst consensus for BMEA over the last few months:
Latest BMEA News
Biomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway Pressure
Biomea Fusion's pipeline centers on icovamenib for beta-cell regeneration in diabetes and BMF-650, an oral GLP-1 agonist. Read why BMEA stock is a hold.
Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data
Biomea Fusion stock falls after ending a public securities offering and revising clinical data timelines for its obesity trial.
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics (NASDAQ:VTGN) shares
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed public offering of securities, previously announced on September 22, 2026. The termination results from an assessment by the Company's management that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company's stockhold
Biomea Fusion Terminates Proposed Public Offering Of Securities Due To Market Conditions
Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed public offering of securities, previously
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.
Biomea Fusion Shares Fall 19% After Hours: Here’s Why
Biomea Fusion shares fall nearly 19% after hours, highlighting volatility in BMEA after Tuesday's session.
These stocks are moving in today's after hours session
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Biomea Fusion Announces Proposed Public Offering of Securities
SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Biomea intends to grant the underwriter a 30-day option to purchase up to an additional fifteen percent (15%) of the total numb
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's after-market session. The company's market cap stands at $1.1 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares
Biomea Fusion Says Topline Data From Phase 1 Obesity Trial Of BMF-650 Now Expected In October, Pushed From Q3
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001840439/000119312526397870/bmea-20260922.htm
Biomea Fusion, Inc. (BMEA) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow
2026-09-16. The following slide deck was published by Biomea Fusion, Inc.
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-10 | Averill Julianne | +173,711 | - | - |
| 2026-06-10 | Ray Sumita | +196,299 | - | - |
| 2026-06-10 | Faust Elizabeth | +196,299 | - | - |
| 2026-06-10 | AGUIAR ERIC | +196,299 | - | - |
| 2026-04-01 | Hitchcock Michael J.M. | +667,477 | - | - |
| 2026-04-01 | Erdtmann Rainer M | +452,512 | - | - |
| 2025-12-31 | Erdtmann Rainer M | +50,000 | - | - |
| 2025-12-31 | Erdtmann Rainer M | -50,000 | - | - |
| 2025-12-31 | Erdtmann Rainer M | +50,000 | - | - |
| 2025-12-31 | Erdtmann Rainer M | -50,000 | - | - |
| 2025-12-31 | Erdtmann Rainer M | +50,600 | - | - |
| 2025-12-31 | Erdtmann Rainer M | -50,600 | - | - |
| 2025-12-11 | Erdtmann Rainer M | +30,000 | $1.4333 | $42,999 |
| 2025-12-02 | Hitchcock Michael J.M. | +100,000 | $0.9918 | $99,180 |
| 2025-12-01 | Erdtmann Rainer M | +10,000 | $1.05 | $10,500 |
| 2025-11-28 | Erdtmann Rainer M | +40,000 | $1.1013 | $44,052 |